1. Home
  2. EDIT vs CGBS Comparison

EDIT vs CGBS Comparison

Compare EDIT & CGBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • CGBS
  • Stock Information
  • Founded
  • EDIT 2013
  • CGBS 2018
  • Country
  • EDIT United States
  • CGBS Jersey
  • Employees
  • EDIT N/A
  • CGBS N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • CGBS
  • Sector
  • EDIT Health Care
  • CGBS
  • Exchange
  • EDIT Nasdaq
  • CGBS Nasdaq
  • Market Cap
  • EDIT 108.1M
  • CGBS 110.7M
  • IPO Year
  • EDIT 2016
  • CGBS N/A
  • Fundamental
  • Price
  • EDIT $1.25
  • CGBS $0.20
  • Analyst Decision
  • EDIT Buy
  • CGBS
  • Analyst Count
  • EDIT 14
  • CGBS 0
  • Target Price
  • EDIT $8.08
  • CGBS N/A
  • AVG Volume (30 Days)
  • EDIT 2.5M
  • CGBS 1.4M
  • Earning Date
  • EDIT 03-05-2025
  • CGBS 01-01-0001
  • Dividend Yield
  • EDIT N/A
  • CGBS N/A
  • EPS Growth
  • EDIT N/A
  • CGBS N/A
  • EPS
  • EDIT N/A
  • CGBS N/A
  • Revenue
  • EDIT $32,314,000.00
  • CGBS N/A
  • Revenue This Year
  • EDIT N/A
  • CGBS N/A
  • Revenue Next Year
  • EDIT N/A
  • CGBS N/A
  • P/E Ratio
  • EDIT N/A
  • CGBS N/A
  • Revenue Growth
  • EDIT N/A
  • CGBS N/A
  • 52 Week Low
  • EDIT $1.12
  • CGBS $0.18
  • 52 Week High
  • EDIT $7.41
  • CGBS $6.91
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 41.70
  • CGBS N/A
  • Support Level
  • EDIT $1.24
  • CGBS N/A
  • Resistance Level
  • EDIT $1.32
  • CGBS N/A
  • Average True Range (ATR)
  • EDIT 0.11
  • CGBS 0.00
  • MACD
  • EDIT -0.03
  • CGBS 0.00
  • Stochastic Oscillator
  • EDIT 2.94
  • CGBS 0.00

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About CGBS Crown LNG Holdings Limited Ordinary Shares

Crown LNG Holdings Ltd is an LNG infrastructure company that seeks to provide natural gas liquefaction, storage, and re-gasification services. It focuses on enabling a stable and reliable supply of LNG to customers, especially in geographic areas where onshore or floating facilities may be difficult or less desirable as a result of harsh weather conditions, safety or environmental concerns, or cost. It specializes in the design and operation of offshore, all-weather LNG liquefication and re-gasification terminals, such as gravity-based structures. Through Its technologies and design, It believes it can deliver tailored LNG infrastructure suitable for energy-isolated locations, as well as provide critical LNG infrastructure to under-served markets around the world.

Share on Social Networks: